What is Stem Cell TherapyMarket?
With the increasing advances in science and technology and awareness about stem cell therapy has also increased. In many countries with universal health coverage, individuals may be paid by the government to be treated in other countries. These steps improve the patientís accessibility and hence, the perception to consider stem cell as a feasible option.Stem cells are the most vital cells that are found in both humans and non-human animals. Stem cells are also known as the centerpiece of regenerative medicine. Regenerative medicines have the capability to grow new cells and replace damaged and dead cells. The stem cell is the precursors of all cells in the human body that has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem cell-based therapies are used in the treatment of several chronic diseases such as cancer and blood disorders.
Increasing cost of stem cell therapy procedure and Technological advancement in healthcare and identification of new stem cell line.
Significant rise in the number of clinical application of stem cells and advantages of stem cell therapies, Rapid infrastructure development and increasing disposable income of the consumers, Increasing awareness among people about therapeutic potency of stem cells and Technology advancement in healthcare curing life threatening diseases and giving promising results.
Rise in Economy and technological advancement may provide opportunities for this market.
The Players Covered in the Study are:
Cellular Dynamics International, Inc. (United States), Osiris Therapeutics (United States), Vcanbio Cell & Gene Corp. Ltd. (United States), Gamida-Cell Ltd. (Israel), Golden Meditech Holdings Limited (Hong Kong), Celgene Corp. (United States), Guanhao Biotech Co. (China), Mesoblast Ltd. (Australia), Vericel Corp. (United States), Stemcell Technologies Inc. (Canada), Beike Biotechnology co., Ltd. (China), Cytori Therapeutics, Inc. (United States), Bioheart Inc. (United States), Universal Cells, Inc. (Japan), Athersys, Inc. (United States), Geron Corp. (United States), Pluristem Therapeutics (Israel), Fibrocell Science (United States), Astellas US Holding, Inc. (United States), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (United States), RTI Surgical, Inc. (United States), AlloSource (United States), Novartis International AG (Switzerland) and Gilead Sciences (United States)
List of players that can be included in the study on immediate basis are Organogenesis Holdings (United States), Vericel (United States), Mesoblast Ltd.(Australia), ReNueron Group plc,(United Kingdom) and International Stem Cell Corp. (United States).